 Patients with HER2-positive tumors 20 mm or verfied regional lymph node metastases are randomized to either arm A, the combination of docetaxel, trastuzumab sc Herceptin SC and pertuzumab Perjeta or arm B, trastuzumab emtansin Kadcyla. Switch to the opposite treatment is performed in case of lack of response after evaluations with mammography and ultrasound, alternatively MRI breast after the 2nd, 4th and 6th course of treatment. 